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Abstract 
Tumor necrosis factor-receptor associated periodic syndrome 
(TRAPS) is a dominantly inherited auto-inflammatory disorder 
caused by mutations in TNFRSF1A, the gene encoding for 
tumour necrosis factor receptor superfamily 1A. The 
mechanism of inflammation in TRAPS is still unknown. In 
particular the involvement of adaptive immunity in auto-
inflammatory disorders hasn’t been investigated yet. In this 
project we investigated how TNF/TNRSF1A signalling 
network regulates T cell responses. In particular, we focused on 
conventional CD4+CD25- (Tconv) and regulatory CD4+CD25+ 
(Treg) T cell functions in TRAPS patients carrying either high 
or low penetrance mutation in TNFRSF1A gene (HP-TRAPS  
and LP-TRAPS, respectively). HP-TRAPS showed an up-
regulation of several inflammation-related molecular signalling 
pathways in Tconv cells. In addition, these patients had a lower 
frequency of peripheral Treg cells which also displayed a 
defective suppressive phenotype. These alterations were 
partially found in LP-TRAPS who also carried a milder 
symptomatology thus suggesting suggest a specific link 
between the penetrance of the TNFRSF1A mutation and the T 
cell phenotype. Taken together, these data envision a novel role 
for adaptive immunity in the pathogenesis of TRAPS involving 
both CD4+ Tconv and Treg cells raising a novel mechanism of 
inflammation in the context of auto-inflammatory disorders.           
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1. Introduction 
 
1.1 Plasticity of adaptive immunity 
A tight cross-talk between the innate and adaptive immune 
systems is necessary in order to achieve an efficient defense 
against invading pathogens. 
Presenting cells such as dendritic cells (DCs), upon antigen 
recognization, help CD4+ T cells to differentiate into a variety 
of effector subsets, Th1, Th2, Th17, follicular helper T (Tfh) 
cells, and induced Treg (iTreg) cells. Cytokines in the 
microenvironment and the strength of the interaction of the T 
cell antigen receptor with antigen orchestrate the differentiation 
pathway (1). Th1 cells are characterized by IFN- production 
and are involved in cellular immunity against intracellular 
microorganisms. The signal transducer and activator of 
transcription 4 (Stat4), Stat1, and T box transcription factor T-
bet are activated during Th1 polarization. 
Th2 cells produce IL-4, IL-5, and IL-13 and are required for 
humoral immunity to control helminths and other extracellular 
pathogens. GATA3 and Stat6 are needed for the differentiation 
of Th2 cells. Th17 cells produce IL-17A, IL-17F, and IL-22 
and play important roles in clearance of extracellular bacteria 
and fungi, especially at mucosal surfaces. Th17 cell 
differentiation requires retinoidrelated orphan receptor 
(ROR)t, a transcription factor that is induced by TGF- in 
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combination with the pro-inflammatory cytokines IL-6, IL-21, 
and IL-23, all of which activate Stat3 phosphorylation (2). Tfh 
cells are a subset of helper T cells that regulate the maturation 
of B cell responses. Differentiation of these cells requires the 
cytokine IL-21 (3, 4) and the expression of the transcription 
factor Bcl-6 (5). 
Regulation of effector T cell responses is required for effective 
control of infections and autoimmune diseases. Aberrant Th1 
and Th17 cell responses play critical roles in organ-specific 
autoimmunity, whereas Th2 cells are mainly involved in 
allergy and asthma. Treg cells have essential roles in 
maintenance of immune homeostasis, regulating these effector 
T cell responses and thus preventing their potentially 
pathogenic effects through a variety of mechanisms (6, 7).  
 
1.2 Treg cells 
Self-tolerance is maintained by CD4+CD25+ regulatory T cells. 
These cells were firstly identified in mice (8) and later in 
humans (9). Treg cells are characterized by the expression of 
the forkhead transcription factor Foxp3 which plays a critical 
role in maintaining their functional program and generation 
(10, 11). Of note, patients affected by immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), 
were found to have mutations in the Foxp3 gene thus 
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supporting the hypothesis of a pivotal role of Treg cells in the 
regulation of immune tolerance (12). 
Two major categories of Foxp3+ Treg cells have been identified 
so far: the naturally occurring CD4+CD25+ Treg (nTreg) cells 
that arise in the thymus and the TGF--induced iTreg cells 
produced in the periphery from Tconv cells (13, 14). In 
humans, CD45RA+CD25+Foxp3+ cells represent thymus-
derived Tregs, while CD45RA- Tregs are a mixed population 
including antigen-experienced thymic and peripheral Tregs 
(15). The stability of Foxp3+ Tregs is debated (16). Foxp3 
regulates distinct cell surface and signalling molecules, 
interacting with several transcription factors, inducing miRNAs 
and modulating epigenetic machinery to maintain Treg identity, 
function and stability in response to diverse environmental 
cues.  
Tissue microenvironment influences the functional 
specialization of Foxp3+ Treg. Indeed, Treg can lose the 
capability to express Foxp3 with the acquisition of an effector 
phenotype in presence of an abundance of pro-inflammatory 
stimuli (17, 18). 
In mice, only very small fractions of Foxp3+ Tregs were found 
to lose Foxp3 and regulatory functions (18). In humans, 
CD45RA+ but not CD45RA- Tregs could be stably expanded in 
vitro (19), suggesting different stabilities of thymic and 
peripheric Tregs. 
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Tregs also inhibit anti-tumor CTL responses (20), and 
interestingly they can acquire cytotoxic properties in tumor-
draining lymphnodes in mice (21) and in vitro in humans (22, 
23). Similar to helper T cells, Tregs that secrete different types 
of effector cytokines, and these Treg subsets might specifically 
suppress different types of immune responses (24). 
IL-17 or IFN- producing human Foxp3+ T cells can be isolated 
(25, 26), but while IL-17 producing Treg cells were normally 
suppressive (27), IFN- producing Tregs showed reduced 
suppressive functions (26).  
Both natural and induced Treg cells participate in 
maintenance of peripheral tolerance and prevention of 
autoimmunity (28). Alteration of their number and/or their 
suppressive function has been identified in many autoimmune 
disorders (29) but the underlying mechanism is still unknown. 
Many studies have highlighted how immune cells rely upon 
bioenergetic pathways to support their growth, proliferation, 
migration and differentiation. Alteration of these metabolic 
pathways can lead to chronic inflammation and autoimmunity. 
In this context De Rosa et al have recently shown that 
glycolysis is important for Foxp3 expression. Patients with 
multiple sclerosis and type 1 diabetes display impaired rates of 
glycolysis, which in turn determines altered peripheral Treg 
generation and functions (30). 
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Tfr cells are a newly identified CD4 Foxp3+ Treg subset 
located in the germinal centres (GCs) of lymphoid organs, 
which downregulates the GC response by suppressing Tfh and 
B cells functions. Tfh and Tfr cells are defined by expression of 
the CXC-chemokine receptor 5 (CXCR5) which directs them to 
B cell follicles in GCs via gradients of the CXC-chemokine 
ligand 13 (CXCL13). Defects of Tfr number and functions have 
been associated to alteration of the homeostasis of B cells in 
germinal centers favoring the production of autoreactive 
antibodies and the onset of autoimmunity (31).  
 
1.3 Auto-inflammatory disorders 
The field of autoinflammatory disorders (AD) has expanded 
significantly in the last few years. Recent advances in basic 
sciences have provided new insights into the biology of the 
inflammatory responses in AD. 
The term autoinflammatory was coined to differentiate AD 
from autoimmune disorders. Indeed, AD are characterised by 
the absence of pathogens, circulating autoantibodies, or self-
reactive T cells (32). To date, nearly all mutations linked to AD 
have been associated with inflammatory signalling pathways 
regulating innate immune responses. This is following by the 
activation of the inflammasome, a multimeric cytosolic protein 
complex regulating the proteolytic processing of proIL-1β into 
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the biologically active IL-1β thus inducing a vast spectrum of 
systemic inflammatory signs (33). 
The most common AD are: (a) familial Mediterranean fever 
(FMF) associated with mutation in the MEFV gene located on 
the chromosome 16p13.3 and encoding a protein named pyrin, 
a natural repressor of proinflammatory molecules. Ths results 
in uncontrolled relapsing one-site or multi-site inflammation, 
increased leukocyte migration to serosal membranes or joints, 
and inappropriate response to inflammatory stimuli (34); (b) 
tumor necrosis factor receptor-associated periodic syndrome 
(TRAPS) related to mutations in the soluble TNF receptor 
superfamily 1A gene (35); (c) cryopyrin-associated periodic 
syndrome (CAPS), caused by mutations in the NLRP3 gene 
located on the chromosome 1. This group includes familial cold 
urticaria syndrome (FCAS), Muckle-Wells syndrome, and 
chronic infantile neurological cutaneous articular syndrome 
(CINCAs), respectively, ranging from the least to the most 
severe (36); (d) mevalonate kinase deficiency (MKD), also 
known as hypergammaglobulinemia D syndrome, caused by 
homozygosity or compound heterozygosity for disease-causing 
mutations in the MVK gene, which has been localized in the 
chromosome 12q24 and encodes for mevalonate kinase, the 
first committed enzyme of cholesterol biosynthesis (37); (e) 
NLRP12-associated autoinflammatory disorder (NLRP12-ad), 
or FCAS type 2, caused by mutations in the NLRP12 gene, 
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which encodes for the monarch-1 protein, working as a 
regulator of NF-κB activation (38); (f) Blau syndrome (BS), 
genetic form of a condition previously known as “early onset 
sarcoidosis”, due to mutations of the NACHT domain of the 
gene CARD15 (also renamed NOD2) (39). 
Some of these diseases such as FMF and MKD are transmitted 
by autosomal recessive inheritance, while the others such as 
TRAPS, CAPS, NLRP12-ad, and BS are autosomal dominant. 
Table 1 summarizes the main clinical features of AD. 
In addition to the monogenic AD, many other syndromes, 
sharing similar overlapping manifestations with 
autoinflammatory conditions, such as systemic juvenile 
idiopathic arthritis, Still’s disease, gout, idiopathic recurrent 
pericarditis, generalized pustular psoriasis, Schnitzler’s 
syndrome, Behçet’s disease, periodic fever aphthous stomatitis, 
pharyngitis and cervical adenitis (PFAPA) syndrome, and many 
other rare or even frequent conditions, have been included in 
the group of polygenic multi-factorial AD (40). 
Most of the monogenic AD has a general clinical onset 
during the pediatric age (41, 42). However, a substantial 
number of patients may have a disease onset during adulthood. 
The main clinical features are recurrent brief episodes of fever, 
serositis, joint symptoms, and erysipelas-like erythema in the 
lower limbs. Of note, long-term exposure to uncontrolled 
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inflammation can lead to development of amyloidosis. A late 
onset syndrome is mostly associated with the presence of low 
penetrance mutations, milder phenotypes, and a lower risk of 
developing amyloidosis (43, 44).  
Diagnosis of specific AD relies on patient’s clinical history, 
demonstration of increased acute phase response during 
inflammatory attacks, and possibly, genetic confirmation (45). 
The introduction of biologic agents has strongly changed the 
course and prognosis od AD. In particular, TNF-α and IL-1 
blockers have significantly improved overall patients’ quality 
of life and prognosis with a good control of systemic symptoms 
(46). 
Even though genetic mutations mainly involve proteins 
implicated in innate immune responses, adaptive immune 
system might be implicated as well. 
In this regard, patients with CAPS have shown higher levels of 
Th17 cells without a clear autoimmune syndrome (47). 
According to this, a recent paper by Arbore et al has 
demonstrated that NLRP3 inflammasome activity within CD4+ 
T cells is necessary to drive Th1 differentiation and for the 
production of optimal IFN-γ responses during a viral infections. 
They also showed that patients with CAPS had hyperactive T 
Th1 responses, and that this was associated with increased IL-
1β and IFN-γ production by Th1 cells. (48) 
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Therefore, it seems that the interplay between the innate and 
adaptive immune responses may be even stronger than 
previously thought. 
 
1.4 TRAPS 
Tumour necrosis factor (TNF)-α is produced by 
epithelial and immune cells (49-52) and regulates several 
biological processes including immune responses, 
inflammation, apoptosis, cell differentiation and proliferation. 
This is due to the binding to TNF receptors TNFRSF1A (or 
TNFR1A p55/p60-TNFR) and TNFR1B (or TNFR2, p75/80-
TNFR) (53, 54). TNFRSF1A is constitutively expressed in 
many cell types including macrophages, neutrophils, mast cells 
and lymphocytes and mediates TNF-α signalling through the 
recruitment of various intracellular proteins. This results in the 
activation of transcription factors such as NF-kB and AP-1, 
apoptosis pathways and mitogen-activated protein kinase 
(MAPKs) signalling (55-57). Mutations in the TNFRSF1A gene 
that encode for TNFRSF1A receptor are known to be 
associated to an autosomal dominant auto-inflammatory 
syndrome known as tumour necrosis factor-receptor associated 
periodic syndrome (TRAPS) (58, 59). The auto-inflammatory 
syndromes are a growing group of conditions characterized by 
impaired innate immune response associated to generalised 
systemic inflammation without involvement of auto-antibodies 
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and auto-reactive T cells (40). TRAPS is clinically 
characterized by recurrent fever attacks, periorbital oedema, 
conjunctivitis, a migratory skin rash, myalgia, arthralgia and/or 
arthritis, polyserositis and amyloidosis as more severe 
complication (60-65). Several TNFRSF1A mutations have been 
found associated to TRAPS (http://fmf.igh.cnrs.fr/infevers/). 
Most of these mutations are heterozygous missense and 
localized in the extracellular portion of the receptor (66). 
TRAPS-associated mutations can be high-penetrance (HP-
TRAPS) also called “structural mutations” mainly affecting 
cysteine residues. These mutations generally involve the 
receptor folding and are associated related to a more severe 
phenotype. On the other side, low-penetrance (LP-TRAPS), 
defined as "non-structural mutations or variants of unknown 
significance" mainly associated to milder symptoms, lower risk 
of amyloidosis and shorter duration of attacks (60, 61, 43, 67, 
68). The precise pathogenic mechanism of TRAPS is not well 
understood. It has been observed that TRAPS-associated 
mutations can alter TNFRSF1A cell surface expression, 
shedding, TNF-α binding affinity, TNFRSF1A intracellular 
trafficking as well as TNFα/TNFRSF1A signalling and 
autophagy (67, 69-74). Recently it has been demonstrated that 
peripheral blood leukocytes isolated either from TRAPS 
patients or mice with TNFRSF1A mutations, showed increased 
MAPKs activation after LPS stimulation due to intracellular 
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receptor accumulation (75). These cells also exhibited 
increased mitochondrial respiration and unconventional 
unfolded protein response leading to reactive oxygen species 
(ROS) production, events known to potentiate MAPKs 
signalling as well as secretion of several pro-inflammatory 
cytokines (76-78). 
 Since little is known about the involvement of adaptive 
immunity in the pathogenic events leading to TRAPS 
symptoms, we investigated the impact of TNFRSF1A 
mutations on different T cell subsets. Specifically, we 
delineated how multiple variants of TNFR1 mutations are able 
to affect, the T conventional/ T regulatory (Tconv/Treg) 
balance thus providing novel insights into the detailed 
molecular mechanisms regulating immune self-tolerance in 
TRAPS disease. 
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2. Materials and Methods 
2.1 Patients 
 Serum and blood samples were obtained from 20 HP-
TRAPS (C43R 2/35 pts; C43T 1/35 pts; T50M 7/35 pts; C52Y 
2/35 pts; C125R 2/35 pts; C55Y 1/35 pts; S59N 1/35 pts; S59P 
1/35 pts; C114W 1/35 pts; Del 103-104 1/35 pts; L167-175del 
1/35 pts), 15 LP-TRAPS (R92Q 12/35 pts; D12E 1/35 pts; 
V95M 1/35 pts; R104Q 1/35 pts) and from 32 age-, gender- and 
BMI-matched healthy controls (HC) without inflammatory 
diseases (17 males, 15 females) (42 years; range 9-65) 
attending the outpatient clinic at the Rheumatology Unit of the 
University of Siena, for fibromyalgia and/or carpal tunnel 
syndrome and who tested negative for TRAPS mutations. 
These subjects underwent detailed clinical and laboratory 
workup, in order to rule out any inflammatory, metabolic, and 
neoplastic disorders. Laboratory assessment included 
erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), and serum amyloid A (SAA). ESR was measured using 
the Westergren method (mm/hour), and was considered normal 
if 15 < mm/hour for males and < 20 mm/hour for females. 
Serum CRP concentrations were measured using a 
nephelometric immunoassay, values 0.5 mg/dL were 
considered normal. Serum amyloid A (SAA) levels were 
measured by particle-enhanced nephelometry (BNII auto-
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analyzer, DadeBehring, Marburg, Germany) and the reference 
value was 6.4 mg/L.  
 Written informed consent was obtained both from 
patients and controls. The study protocol was reviewed and 
approved by the University of Siena Institutional Ethics 
Committee in according the Declaration of Helsinki. Clinical 
and demographic characteristics of HP- and LP-TRAPS 
patients, at the time of blood collection, are summarized in 
Table 2. All samples have been collected during a remission 
phase of the disease at routine follow-up.  
 
 2.2 Immunephenotype 
 Immune cell profiling of cells from TRAPS patients and 
HC subjects was done at the time of the blood draw. Before 
flow cytometry to determine lymphocyte subsets, whole blood 
cells were analysed with a clinical grade hematocytometer to 
determine absolute lymphocyte numbers in each sample. For 
the HC subjects and TRAPS patients, 100µL blood was 
incubated 30min at room temperature with the specific 
antibodies combinations. Erythrocytes were lysed using BD 
FACS lysing Solution 2 (BD Bioscience) for 10 min and 
subsequently washed and resuspended in 300L PBS. Flow 
cytometry was carried out on cells gated on CD45+-SideScatter 
(SSC). Immunephenotypic analysis was performed with an 
EPICS XLflow cytometer (Beckman Coulter) using the 
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Beckman Coulter XLSystem II software program. Triple 
combinations of different human monoclonal antibodies (i.e., 
fluorescein isothiocyanate [FITC]– and phycoerythrin [PE]–
anti-CD3, PE– and PC-5–anti-CD4, PC5–anti-CD8, PE–anti-
CD16, PC5–anti-CD19, PE–anti-CD25, FITC–anti-CD45, and 
PE–anti-CD56; all from Coulter Immunotech) were used to 
identify different cell populations. 
 
2.3 Cell cultures and T cell proliferation assays 
 Human peripheral blood mononuclear cell (PBMCs) 
were isolated by stratifying 15 mL of heparinized whole blood 
on 5 mL of Ficoll-Paque PREMIUM (GE Healthcare) and 
centrifuging the solution at 1.2×g for 20 min. PBMCs (2×105 
per well) were cultured, in triplicate, in 96-well round-
bottomed plates (Becton-Dikinson Falcon), in medium 
supplemented with 5% (vol/vol) autologous (AS) subject serum 
or 5% (vol/vol) heterologous (HS) commercial pooled AB 
human serum (Sigma-Aldrich, St. Louis, MO) and were 
stimulated or not in parallel with 0.1 μg/mL anti-CD3 
monoclonal antibody (OKT3, Orthoclone, Janessen-Cilag 
SpA). Supernatants were collected from 48h TCR-stimulated 
PBMCs from TRAPS patients and HC subjects. The human 
Th1/Th2 11plex kit FlowCytomix (Bender Medsystems 
GmbH) was used for quantitative detection of human interferon 
(IFN)-γ, tumor necrosis factor (TNF)-α, TNF-β, interleukin 
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(IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, by flow 
cytometry (Becton-Dickinson) according to the manufacturer’s 
instructions.  
 Human CD4+CD25+ (Treg) and CD4+CD25- (Tconv) T 
cells were purified from HC and TRAPS patients PBMCs by 
magnetic cell separation with the DynalCD4+CD25+ Treg Kit 
(Dynal-Biotech) and were rapidly cleaned with the Detach 
reagent (Dynal-Biotech) from surface-bound CD25 mAb. 
Magnetic beads-based-based purification technique yielded a 
highly expressing CD25+ population (98% pure by FACS 
analysis), 90% of which expressed Foxp3. The Treg:Tconv 
ratio in the suppression experiments was 1:1. We cultured cells 
(1×104 cells per well) in round-bottom 96-well plates (Becton-
Dickinson Falcon) with RPMI 1640 medium supplemented 
with 100 UI ml−1 penicillin and 100 μg ml−1 streptomycin (all 
from Life Technologies) and supplemented with either 5% AS 
or 5% AB HS. Cells were stimulated for 48h, in the presence of 
anti-CD3/anti-CD28–coated Dynabeads (0.5 beads per cell) 
(Invitrogen). On the last day, [3H]thymidine (0.5 Ci/well) 
(Amersham-Pharmacia Biotech) was added to the cultures and 
cells harvested after 12h. Radioactivity was measured with a  -
cell-plate scintillation counter (Wallac). 
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 2.4 Flow cytometry  
 On freshly isolated PBMCs from TRAPS patients and 
HC subjects, we performed FACS analysis (BD FACS-Canto). 
For staining isolated Treg cells, we used (1:50–100 dilution) 
APC-H7–labeled anti–CD4 (BD Biosciences). Thereafter, cells 
were washed, fixed and permeabilized (fixation-
permeabilization buffer, eBioscience) and stained with PE-
labeled anti-FoxP3 (eBioscience) and FITC-labeled anti-Ki67 
(BD Biosciences) monoclonal antibodies. Analyses were 
performed with Diva software from BD and FlowJo software 
(Tree Star). 
 
2.5 Molecular signalling and western blot analyses 
 Tconv cells (3x105) were lysed in cold radioimmune 
precipitation assay buffer RIPA (50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% 
SDS,protease and phosphatase inhibitors) for 15 min at 4°C. 
The lysate was centrifuged (10,000 × g for 10 min); the 
supernatant was collected, quantized and resuspended in 
electrophoresis sample buffer, heated to 95°C for 5 min and 
resolved on a SDS 8% polyacrylamide gel. Western blot with 
specific antibodies were used according to the protocol 
provided by the supplier. For all western blot shown 8μg of 
total protein extracts were loaded; antibodies used were: anti-
phospho-STAT1 and anti-STAT1, anti-phospho-STAT3, anti-
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STAT3, anti-phospho-STAT5, anti-STAT5, anti-phospho-S6, 
and anti-S6, (Cell Signaling); anti-ERK1/2, anti-phospho-
ERK1/2, anti-NF-kB p65, anti-actin (Santa Cruz Biotechnology 
Inc.). 
 
2.6 Statistical analysis 
 We used non-parametric Mann–Whitney U or Student's 
T tests. Correlation analyses were performed by using 
Spearman’s correlation coefficients. The statistical software 
used was GraphPad InStat3 version 4.0. Results are expressed 
as mean ± S.E.M. p values ≤ 0.05 were considered statistically 
significant. 
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3. Results 
3.1 CD4+ T cells are increased in HP-TRAPS patients 
We analyzed several immune cell subpopulations in 
peripheral blood from HP-TRAPS (n = 17), LP-TRAPS (n = 
13) and HC (n = 32). Total lymphocytes, CD3+ T cells, CD4+ T 
cells as well as CD3+ T cells with a memory phenotype 
(CD45RO+) were higher in HP-TRAPS. These patients also 
showed an increased number of CD4+CD45RO+ and 
CD8+CD45RA+ T cells compared to HC. Statistically 
significant difference was observed also in the absolute number 
of circulating CD4+CD28+ and CD4+CD25+ cells. They were 
both increased in HP-TRAPS compared to HC (Figure 1, 
Table 3). On the other hand, LP-TRAPS patients had higher 
number of CD3+, CD4+ and CD8+ T cells with a naïve 
phenotype (CD45RA+) than HC (Figure 1, Table 3). 
Differences between HP- and LP-TRAPS patients were found 
in the absolute number of total CD4+ T cells and CD3+ and 
CD4+ T cells with memory phenotype (CD45RO+), as well as 
circulating CD4+CD28+ T cells (Figure 1, Table 3). Finally, 
the frequency of total CD4+CD45RO+ T cells and total 
CD3+CD45RO+ T cells did not correlate with serum amyloid A 
(SAA) levels in both HP and LP-TRAPS (Figure 2). 
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3.2 T cell proliferation and cytokine secretion is impaired 
during T cell receptor stimulation in HP-TRAPS patients 
We evaluated T cell proliferative profile in PBMCs, 
stimulated by physiologic T-cell receptor (TCR) specific 
stimuli (anti-CD3 – OKT3 mAb), from HP-, LP-TRAPS and 
HC.  In order to understand whether soluble serum factors 
(either an endogenous factor or related with the drug treatment 
received by the patients) could affect T cell responses in vitro, 
cells were cultured in medium supplemented with either 5% 
autologous subject serum (AS) or 5% heterologous pooled 
healthy human serum (HS) (Figure 3A). We found a reduced 
proliferation in HP-TRAPS compared to HC in both HS- and 
AS-supplemented culture medium (Figure 3A). No significant 
difference was found between LP-TRAPS and HC, and 
between HP-TRAPS and LP-TRAPS, respectively (Figure 
3A).  
We next measured the concentration of pro- and anti-
inflammatory cytokines in T cell-derived supernatants. HP-
TRAPS showed lower levels of IL-5 and IFN in both HS and 
AS-supplemented culture conditions, while lower levels of 
TNFα, IL-1, IL-6 and IL-12p70 were observed only in AS-
supplemented medium. In addition, significant higher 
concentration of IL-8 was observed in HP-TRAPS compared to 
HC in both HS and AS-supplemented medium. Finally, HP-
TRAPS showed decreased levels of TNF, IL-1, IL-5 and IL-
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12p70 in AS-medium, a lower amount of IFNin HS-medium, 
and reduced IL-5 in both HS and AS-media as compared with 
LP-TRAPS. No significant difference was observed in 
cytokines production between LP-TRAPS and HC in both HS 
and AS-supplemented media (Figure 3B-J). 
 
3.3 Tconv proliferation is increased in HP-TRAPS patients 
during TCR stimulation 
We then analyzed the impact of TNFRSF1A mutation 
on Tconv (CD4+CD25-) cells which are generally increased in 
both autoimmune and inflammatory disorders (79). 
Specifically, we evaluated TRAPS Tconv cells proliferation 
during anti-CD3/anti-CD28 stimulation. HP-TRAPS Tconv cell 
proliferative rate was higher than that of HC and LP-TRAPS 
(Figure 4A). In addition, HP-TRAPS Tconv cells showed also 
a higher expression of several intracellular pathways related to 
proliferation and activation such as ERK1/2, STAT1, STAT3, 
STAT5 and NF-kB p65 compared to HC. Whereas, LP-TRAPS 
Tconv cells showed higher expression of STAT1 compared to 
HC Tconv cells (Figure 4B). We further analyzed the 
mammalian target of rapamycin (mTOR) pathway evaluating 
the activation of S6, a downstream target of mTOR. We found 
that S6 phosphorylation was significantly higher in HP-TRAPS 
than HC, while no significant difference was observed between 
LP-TRAPS and HC (Figure 4B). 
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3.4 Treg cell frequency and suppressive function is altered in 
HP-TRAPS patients 
To get further insights into the mechanisms involved in 
a possible break of self-tolerance in TRAPS, we analyzed the 
Treg cell compartment. Indeed, it is well delineated that Treg 
cells display a central role in the regulation of immune 
homeostasis by reducing inflammatory responses and 
suppressing Tconv cells functions (80, 81). We found that HP-
TRAPS had a lower frequency of CD4+FoxP3+ Treg cells than 
HC, while no difference was found between HP- and LP-
TRAPS and between LP-TRAPS and HC, respectively (Figure 
5A, B). In addition, HP-TRAPS Treg cells showed a reduced 
ex-vivo proliferation rate as suggested by a lower expression of 
the Ki67, an intracellular proliferative marker than HC and LP-
TRAPS Treg cells. No difference was found comparing LP-
TRAPS and HC Treg cells (Figure 5C, D). In contrast, HP-
TRAPS Treg cells exhibited a higher proliferative rate in vitro 
during anti-CD3/anti-CD28 stimulation compared to TRAPS-
LP and HC Treg cells despite it did not reach a statistical 
significance (p = 0.06) (Figure 5E).  
 Finally, we analyzed the suppressive capacity of Treg 
cells isolated from HP-, LP-TRAPS and HC. We evaluated the 
Tconv cell proliferation when co-cultured with Treg cells. HP-
TRAPS Treg cells showed reduced suppressive capacity 
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compared to LP-TRAPS and HC while no significant 
difference was observed in LP-TRAPS compared to HC 
(Figure 4E, F). A similar trend was also detected in HS 
medium although it was not significant (Figure 6A, B). 
 
3.5 Meta-immunological profiling in TRAPS patients 
To characterize the meta-immunological profile of TRAPS, 
several indicators of inflammatory and metabolic activities 
were also analyzed in sera from both HP- and LP-TRAPS and 
HC (leptin, MCP-1, MPO, sCD40L, sICAM-1, resistin and 
sTNF-R). The serum concentration of leptin was significantly 
higher in LP-TRAPS than HP-TRAPS (p=0.0427) and HC 
(p=0.0137) serum samples. No difference was found between 
HP-TRAPS and HC. Interestingly sTNF-R levels were lower in 
HP-TRAPS compared to LP-TRAPS (p=0.016) and HC 
(p=0.0051) (Figure 7). sICAM-1 resulted higher in both HP- 
(p=0.0053) and LP-TRAPS (p=0.0046) than in HC. In addition 
we observed that MPO levels were higher in HP-TRAPS than 
HC (p=0.0117). Finally, there was no difference in the serum 
levels of sCD40L, MCP-1, resistin and IL-6 between patients 
and controls (Figure 7). 
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4. Discussion 
 In this study we report that TNFRSF1A mutation 
strongly impacts on adaptive immune compartment thus 
suggesting a key role of T cells in the pathogenesis of TRAPS. 
In this regard, HP-TRAPS patients showed a selective increase 
of CD4+ T cells which displayed a memory (CD4+CD45RO+) 
and an effector phenotype with over-expressed markers of T 
cell activation such as the CD25 (known as the IL-2R alpha 
chain) and CD28. This is a classic feature of autoimmune 
disorders where a peripheral conversion of naïve CD4+ T cells 
into a memory phenotype has often been described. The 
frequency of peripheral memory CD4+CD45RO+ did not 
correlate with disease activity (serum SAA levels) in both HP- 
and LP-TRAPS confirming that the observed altered 
immunologic profile was to be ascribed to a defective TNFR 
signalling pathway more than to the inflammatory milieu (79). 
In line with this evidence, all patients were in a remission phase 
of the disease when were enrolled in the study and blood 
sampling. 
We next evaluated TRAPS PBMCs function during a 
TCR-dependent stimulation, which selectively stimulates the 
whole T cell compartment. Surprisingly, HP-TRAPS T cells 
displayed a reduced proliferative rate compared to HC T cells 
in either HS or AS-supplemented culture medium. This result is 
may be ascribed to an impairment of T cell antigen 
25 
 
presentation/co-stimulation in the context of PBMCs, 
secondary to the altered TNFRSF1A signalling. Our hypothesis 
is related to the finding that anti-CD3 mediated T cell 
proliferation of PBMCs needs the presence of abundant 
antigen-presenting cells (APCs) which must carry on their 
surface MHC-II, and co-stimulatory molecules, whose 
expression is linked to TNFR-signalling. Clearly, further 
studies need to be performed to better explain this 
phenomenon. In line with this result, we also found that anti-
CD3 stimulated HP-TRAPS PBMCs secreted lower amounts of 
several cytokines, indicating a T-cell impaired activation as 
well. Surprisingly, IL-8 was the only cytokine increased in HP-
TRAPS anti-CD3 stimulated PBMCs supernatants. IL-8 is a 
well-known cytokine involved in neutrophils activation and 
chemotaxis, thus confirming the involvement of these cells in 
the pathogenesis of TRAPS as previously reported (82, 67). In 
line with this evidence, we found in HP-TRAPS serum 
samples, high levels of myeloperoxidase (MPO). Of note, we 
ruled out that medications present in TRAPS serum could have 
an impact on T cell mediated responses. Indeed, we did not find 
difference in terms of T cell proliferation/cytokine profiles 
between culture media supplemented either with AS or HS in 
both HP- and LP-TRAPS. 
In order to provide a novel mechanism of inflammation 
at the basis of TRAPS, we also analyzed functional aspects of 
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isolated Tconv and Treg cells. Surprisingly, we found an 
enhanced Tconv proliferative response in HP-TRAPS 
associated with a high expression of multiple inflammatory 
signalling pathways such as STAT1, STAT5, STAT3, ERK1/2, 
NFkb p65, and S6 irrespective of the pro-inflammatory milieu 
as previously described in TRAPS PBMCs (83). These results 
could be explained by a “constitutive activation”, induced by 
mutated TNFR1, of the above inflammatory intracellular 
signalling pathways. This evidence could in part justify the 
diverse pathophysiology of TRAPS and the limited efficacy of 
cytokine-blocking biological agents. Furthermore, LP-TRAPS 
Tconv cells had an intermediate/mild phenotype, since they 
behaved very similarly to HC Tconv cells, showing only an 
elevated expression of STAT1. This latter result is of high 
interest since it has been reported that STAT1 signalling plays a 
central role in IL-1 activation (84) and helps to understand 
why symptomatic LP-TRAPS patients benefit from anti-IL-1 
treatment. In summary, while the whole T cell population of 
PBMCs showed a reduced proliferative rate during anti-CD3 
stimulation, when CD4+ Tconv cells were isolated from 
PBMCs they showed a higher proliferative phenotype 
secondary to an enhanced mTOR-STATs signalling.  
 On the side of immune tolerance, HP-TRAPS patients 
showed a reduced frequency of peripheral CD4+FoxP3+ Treg 
cells which expressed a defective suppressive capacity 
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compared to LP-TRAPS and HC Treg cells. One of the 
immune abnormalities observed in autoimmune disorders, is a 
reduction in the suppressive function and/or number of natural 
Treg cells (85-87). Under normal circumstances, Treg cells are 
typically hyporesponsive to TCR stimulation in vitro and 
highly proliferative in vivo. Moreover, it is well delineated that 
in vitro Treg cell anergy (a state of hyporesponsiveness to 
antigenic stimulation) is crucial for an optimal suppressive 
function (80). In our study, we observed that HP-TRAPS Treg 
cells had a higher proliferation after TCR stimulation in vitro 
(reduced anergy) with a lower expression of Ki67+ ex-vivo. 
This may explain the Treg impaired suppressive function and 
higher Tconv proliferative response in HP-TRAPS. These 
alterations were not found in patients carried low penetrance 
mutations. In this context, it has been recently shown that 
TNFR1 is crucial for Treg cell functions: thus, alterations 
involving the expression of this receptor on T cell surface may 
promote inflammatory responses (88) and our data are in 
agreement with this recent finding. 
Taken together, our report unveils a novel mechanism 
of inflammation in TRAPS involving CD4+ T cells (both Tconv 
and Treg cells) and reveals a novel scenario in which a 
dysfunction in the regulatory immune-cell compartment is 
present in the context of auto-inflammatory disorders, 
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previously considered mainly ascribed to an altered innate 
immune response. 
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Figure 1. Immunephenotype of TRAPS patients with low and 
high penetrance TNFRSF1A variants. HP-TRAPS (n = 17; 2 
C43R, 1 C43T, 7 T50M, 2 C52Y, 2 C125R, 1 C55Y, 1 S59P, 1 
Del 103-104); LP-TRAPS (n = 13 ; 10 R92Q, 1 R104Q, 1 
D12E, 1 V50M); HC (n = 32).Data are expressed as mean ± 
s.e.m. Statistical significance was determined using Mann-
Whitney non-parametric U-test. *p ≤ 0.05, **p ≤ 0.03, ***p ≤ 
0.01, ns = not significant. 
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Figure 2. Correlations of CD3+ and CD4+ phenotypes and 
serum amyloid A levels from peripheral blood of HP-TRAPS 
and LP-TRAPS patients. Total CD3+, CD4+ and 
CD4+CD45RO+ and CD3+CD45RO+ T cells were correlated 
with serum amyloid A levels (SAA, mg/L) Values were 
obtained using Spearman’s correlation coefficients. 
Correlations were considered significant at p < 0.05. 
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Figure 3. PBMCs proliferative profile and cytokine release in 
TRAPS patients and HC during anti-CD3 stimulation. (A) 
Proliferation (CPM-3H incorporation) and (B-J) cytokine 
production (pg/ml) of PBMCs isolated from TRAPS patients 
with high (n = 10) and low penetrance (n = 7) TNFRSF1A 
mutation and HC (n = 16) after TCR-mediated stimulation 
(anti-CD3) in medium supplemented with heterologous (HS) or 
autologous (AS) serum. Data are expressed as mean ± s.e.m. 
Statistical significance was determined using Mann-Whitney 
non-parametric U-test. *p ≤ 0.05, **p ≤ 0.03, ***p ≤ 0.01, ns = 
not significant.  
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Figure 4. Enhanced activation and proliferation of Tconv cells 
in HP-TRAPS associates with an increased STATs-mTOR 
signalling. (A) Proliferation (CPM-3H incorporation) of anti-
CD3/CD28-stimulated Tconv cells from HP-TRAPS (n = 5; 2 
C52Y, 1 T50M, 1 DEL103-104, 1 S59P), LP-TRAPS (n = 5; 3 
R92Q, 1 D12E, 1 R104Q) and HC (n = 7). Cells were cultured 
in 5% AS medium and stimulated with 0.5 beads per cell for 
48h. (B, C) Western blot analysis of P-ERK1/2, P-STAT1, P-
STAT3, P-STAT5, NF-kB p65 and P-S6 in 24h anti-
CD3/CD28-stimulated Tconv cells in HP-, LP-TRAPS and HC. 
Cells were cultured in 5% AS-supplemented medium and were 
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stimulated with 0.2 beads per cell. Data are representative of at 
least three independent experiments and are expressed as mean 
± s.e.m. Statistical significance was determined using unpaired 
Student's T-test. *p ≤ 0.05, **p ≤ 0.03, ns = not significant. 
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Figure 5. HP-TRAPS patients show a reduced Treg cell 
number and suppressive function. (A) Foxp3 expression in 
freshly-isolated PBMCs from HP-TRAPS (n = 15; 2 C43R, 1 
C43T, 2 C52Y, 2 C125R, 6 T50M, 1 DEL103-104, 1 S59P), 
LP-TRAPS (n = 12; 9 R92Q, 1 R104Q, 1 D12E, 1 V95M) and 
HC (n = 15). PBMCs were stained for CD4 and Foxp3 
expression. (B) Representative flow cytometry plots of Foxp3 
expression in freshly isolated PBMCs from HP-, LP-TRAPS 
and HC. (C) Ki67 expression in freshly isolated Treg cells 
defined by gating CD4+Foxp3+ cells from HC (n = 11), HP-
TRAPS (n = 8; 2 C125R, 4 T50M, 1 DEL103-104, 1 S59P) and 
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LP-TRAPS (n = 5; 4 R92Q, 1 R104Q). (D) Representative flow 
cytometry plots of Ki67 expression in freshly isolated PBMCs 
gated on CD4+Foxp3+ from HP-, LP-TRAPS and HC. (E) 
Proliferation of anti-CD3/CD28 stimulated Tconv and Treg 
cells from HP- (n = 5; 2 C52Y, 1 T50M, 1 DEL103-104, 1 
S59P), LP-TRAPS (n = 5; 4 R92Q, 1 D12E) and HC (n = 7) 
alone or in co-culture. (F) Percentage of suppression of Tconv 
cells proliferation when in co-culture with Tconv cells. Treg : 
Tconv cells ratio in the suppression experiments was 1:1. Cells 
were cultured in 5% AS-supplemented medium and stimulated 
with anti-CD3/CD28 (0.5 beads per cell) for 48h. Comparisons 
were evaluated using the non-parametric Mann Whitney U test. 
Data are reported as the mean ± s.e.m. *p ≤ 0.05, **p ≤ 0.03, ns 
= not significant
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Figure 6. Tconv, Treg proliferative potential and Treg 
suppressive capacity in TRAPS patients with low and high 
penetrance mutation cultured in heterologous serum. 
Proliferation (A) and percentage of suppression (B) of anti-
CD3/CD28 stimulated Tconv and Treg cells from HP-TRAPS 
(n=5), LP-TRAPS (n = 3) and HC (n = 5) alone or in co-
culture. Treg cells: Tconv cells conventional ratio in the 
suppression experiments was 1:1. Cells were cultured in 5% HS 
medium and were stimulated for 48h with anti-CD3/CD28 (0.5 
beads per cell). Comparisons were evaluated using the non- 
parametric Mann Whitney U test. Data are reported as the mean 
and s.e.m. ns = not significant.  
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Figure 7. Meta-immunological profiling in HP-and LP-TRAPS 
patients and CTR subjects. Circulating level of sCD40L, TNF-
R, MCP-1, MPO, leptin, sICAM-1, resistin, IL-6  in TRAPS 
patients with HP TNFRSF1A mutation (n = 20; 2 C43R, 1 
C43T, 7 T50M, 2 C52Y, 2 C125R, 1 C55Y, 1 S59N, 1 S59P, 1 
C114W, 1 Del 103-104, 1 L167-175del), LP mutation (n = 9; 6 
R92Q, 1 R104Q, 1 D12E, 1 V50M) and CTR subjects (n = 32). 
Data are expressed as mean ± s.e.m. statistical significance was 
determined using Mann-Whitney non parametric U-test. 
***p≤0.01, **p≤0.03, *p≤0.05. 
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Table 1: Monogenic autoinflammatory disorders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease 
 
Gene 
 
Protein Trasmission Symptoms 
 
Therapy 
 
 
FMF 
 
MEFV 16p13.3 
 
Pyrin 
 
AR 
 
Short duration of fever episodes: 24–48 hours. 
Abdominal and chest pain. Erysipelas-like erythema. 
High incidence of renal amyloidosis in untreated patients. 
Good response to colchicine. 
Possible response to IL-1 blockade. 
 
Colchicine 
 
 
 
HIDS 
 
 
 
MVK 12q24 
 
 
 
Mevalonate kinase 
 
 
 
AR 
 
Early onset (usually <12 months). 
Mean duration of fever episodes: 4–5 days. 
Poor conditions during fever episodes. Abdominal pain, 
vomiting and diarrhoea. Splenomegaly. 
Good response to steroids. High rate of self-resolution 
during adulthood. Amyloidosis is rare. 
 
 
FANS, 
anakinra 
 
 
TRAPS 
 
 
TNFRSF1A 
 
p55 TNF-α receptor  
 
AD 
 
Prolonged fever episodes: 1–3 weeks. 
Periorbital oedema, monocytic fasciitis. 
Incidence of renal amyloidosis: 15‒25%. 
Response to TNF- and IL-1 blockade. 
 
 
Etanercept, anakinra 
 
 
 
FCAS 
 
MWS 
 
CINCA 
 
 
 
 
 
NLRP3 
 
 
 
 
 
Criopyrin 
 
 
 
AD 
 
AD 
 
AD 
 
FCAS: rash, fever and arthralgia after cold exposure. 
MWS: recurrent or sub-chronic urticaria-like lesions, 
sensorineural hearing loss, amyloidosis. 
CINCA: as above + mental retardation, chronic aseptic 
meningitis and bone deformities. 
Good response to IL-1 blockade. 
 
 
 
 
Etanercept, anakinra 
 
PAPAs 
 
PSTPIP1 
 
PSTPIP1 
 
AD 
 
Pyogenic sterile arthritis, pyogenic gangrenosum, cystic 
acne. Good response to IL-1 blockade. 
Corticosteroids, 
infliximab, 
anakinra 
 
MS 
 
DIRA 
 
 
 
LPIN2 18p 
 
IL1RN 2q 
LPIN2 
 
LPIN2 
 
IL-1 receptor 
antagonist 
 
AR 
 
AR 
 
 
 
Multifocal osteomyelitis, congenital dyserythropoietic 
anaemia, inflammatory dermatosis. 
Neonatal-onset multifocal osteomyelitis, periostitis, and 
pustulosis. Dramatic response to anakinra. 
Corticosteroids, 
interferon 
 
 
BS 
 
 
NOD2/CARD1
516q12.1-13 
 
NOD2/CARD15 AD 
Early onset (<5 years). 
Polyarticular granulomatous arthritis, uveitis, skin rash. 
Good response to anti-TNF monoclonal antibodies. 
Corticosteroids, 
infliximab 
 
 
FMF = Familial Mediterranean fever; MKD = Mevalonate kinase deficiency; TRAPS = TNF receptor associated periodic 
syndrome; FCAS = Familial cold autoinflammatory syndrome; MWS = Muckle-Wells syndrome; CINCA = Chronic infantile 
neurological cutaneous and articular syndrome; PAPA = Pyogenic sterile arthritis, pyoderma gangrenosum and acne (PAPA) 
syndrome; CRMO = Chronic recurrent multifocal osteomyelitis; DIRA = Deficiency of theinterleukin-1-receptor antagonist; AR = 
autosomal recessive; AD = autosomal dominant. 
 Table 2. Clinical and demographic characteristics of TRAPS 
patients with high and low penetrance TNFRSF1A (at the time 
of sample collection), expressed as median (range). 
 
 
 
HP-TRAPS 
 (n = 20) 
 
LP-TRAPS  
(n = 15) 
Age 44 (9-71) 36 (8-56) 
Gender 8M:12F 7M:8F 
Disease onset (yrs) 6 (1-49) 15 (3-55) 
No of fever attacks per 
year 
5 (0-14) 2 (0-15) 
Duration of fever attacks 
(days) 
8 (0-20) 8 (0-25) 
ESR (mm/h) 6 (1-45) 12 (1-31) 
CRP (mg/dL) 0.65 (0-11.4) 0.31 (0-9) 
SAA (mg/L) 5.70 (0.05-1734) 18.5 (17.8-224.8) 
BMI (Kg/m2) 
Amyloidosis 
23.6 (19.0-28.0) 
5/20 
23.4 (21.3-28.7)  
None 
Chronic course 4/20 6/15 
Treated with anti-IL1 15/20  5/15  
Naïve to anti-IL1   
(NSAIDs or 
corticosteroids on 
demand) 
5/20 10/15 
 
 
 
Table 3:  Immunophenotype of TRAPS patients with low and high penetrance TNFRSF1A mutation and healthy controls 
 
Cell type 
HC (n=32) 
Cells/mm3 
(%) 
HP-TRAPS (n=20) 
Cells/mm3 
 
LP-TRAPS (n=13) 
Cells/mm3 
 
p value 
(HC vs 
HP-TRAPS) 
p value 
(HC vs 
LP-TRAPS) 
p value 
(HP-vs 
LP-TRAPS) 
Leucocytes 5786.56 ± 1621.32 7142.11 ± 2989.33 5488.75 ±1848.07 0.1362 0.1382 0.2389 
Lymphocytes 
1775.72 ± 472.41 
 
2574.79 ± 1174.83 1926.38 ± 614.22 **0.0157 0.1225 0.2571 
CD3+ 
1354.44 ± 414.99 
 
1972.11 ± 832.95 1457.86 ± 534.48 **0.0119 0.1172 0.2330 
CD4+ 
821.84 ± 351.83 
 
1288.05 ± 536.32 876.25 ± 327.70 ***0.0019 0.0882 *0.0500 
CD8+ 430.53 ± 155.04 573.89 ± 374.87 408.38 ± 189.51 0.1877 0.2616 0.3794 
CD3-CD16+CD56+ 
 
166.58 ± 113.13 
 
177.42 ± 107.13 240.38 ± 111.24 0.3739 *0.0420 0.1134 
CD19+ 
222.72 ± 108.27 
 
355.42 ± 318.24 199.00 ± 85.31 0.3341 0.4354 0.2697 
CD3+CD45RA+ 
 
565.58 ± 218.14 
 
871.45 ± 565.77 646.61 ± 245.54 **0.0288 **0.0162 0.3506 
CD3+CD45RO+ 
 
796.62 ± 378.92 
 
1100.53 ± 474.84 811.48 ± 337.70 ***0.0062 0.3963 **0.0301 
CD4+CD45RA+ 
 
299.81 ± 140.48 
 
802.23 ± 364.10 502.43 ± 224.07 ***<0.0001 **0.0117 ***0.0013 
CD4+CD45RO+ 
 
523.27 ± 353.22 
 
769.37 ± 502.43 502.43 ± 224.07 ***0.0015 0.3583 **0.0106 
CD8+CD45RA+ 
 
265.76 ± 130.29 
 
379.21 ± 310.00 264.67 ± 141.60 0.1241 ***0.0085 0.4919 
CD8+CD45RO+ 
 
164.77 ± 129.05 
 
160.50 ± 147.87 149.31 ± 92.98 0.1362 0.2008 0.2854 
CD4+CD28+ 
 
766.57 ± 350.48 
 
1172.25 ± 487.60 791.04 ± 282.20 ***0.0014 0.4130 **0.0247 
CD4+CD25+ 19.67 ± 9.60 37.99 ± 48.04 36.82 ± 49.63 0.1107 **0.0240 0.2195 
 
 
 
 
 
 
Abbreviations: HC = healthy controls (n =32); HP-TRAPS = high penetrance TRAPS (n = 20); LP-TRAPS = low penetrance TRAPS (n = 13). 
Data are expressed as mean ± s.e.m. statistical significance was determined using Mann-Whitney non-parametric U-test.*p≤0.05, 
**p≤0.03,***p≤0.01 
 
 
 
CD4+CD8+ 
 
19.62 ± 17.98 
 
32.38 ± 67.73 45.77 ± 96.19 0.4737 0.2553 0.2692 
CD4+DR+ 
 
17.60 ± 12.70 
 
22.90 ± 22.09 19.62 ± 9.8 0.2663 0.2285 0.4788 
CD8+DR+ 
 
14.04 ± 21.36 
 
6.61 ± 11.75 7.03 ± 13.20 *0.0462 0.1839 0.4677 
CD8+CD11b+ 
 
94.30 ± 76.30 
 
96.36 ± 96.10 102.40 ± 120.11 0.3710 0.3629 0.2595 
CD3+CD16+CD56+ 
 
44.19 ± 31.49 
 
75.91 ± 101.63 51.66 ± 41.30 0.4402 0.2952 0.3771 
CD3-CD8+ 
 
75.62 ± 44.06 
 
99.97 ± 101.11 113.49 ± 101.48 0.2895 0.2336 0.3515 
